At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are doing this study to find the best dose of ziftomenib to give with standard chemotherapy in children and young adults with acute leukemia. The people in this study have acute leukemia that keeps growing or came back after treatment. In addition, their cancers have a mutation (change) in the KMT2A, NUP98, or NPM1 genes.
-
Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.
-
Researchers want to learn how well zelenectide pevedotin works against advanced breast cancer. The people in this study have breast cancer that has come back, spread, or cannot be surgically removed. Their cancers are hormone receptor positive/HER2-negative or are triple negative. In addition, their tumor cells have an amplification (too many copies) of a gene called Nectin4.
-
Researchers are comparing ivonescimab with pembrolizumab immunotherapy for the initial treatment of advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread).
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Radiation delivered to metastatic tumors is known to cause damage to the DNA (genetic information) in the cancer cells, which causes them to die. An ATM mutation reduces cancer cells' ability to fix damage to their DNA, making it more likely that the radiation will kill ATM-mutated cancer cells. Lower doses of radiation therapy may cause fewer side effects than standard doses. In this study, researchers will observe the side effects of reduced-dose radiation therapy in patients with metastatic tumors that contain an ATM mutation and the rate at which tumors grow back (recur) after this treatment. It is hoped that lowering the radiation dose will be effective while reducing the side effects of treatment.
-
Researchers are assessing JCAR017 in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The people in this study have CLL or SLL that came back or keeps growing after treatment.
-
Researchers want to know if eating a plant-based diet and taking certain nutritional supplements may be helpful for reducing the risk of progression to multiple myeloma in people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). People with MGUS and SMM have an abnormal protein called the M protein in their blood and are at risk of developing multiple myeloma.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
- A Phase 2 Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia
Full Title A Phase 2 Study of Azacitidine and Venetoclax to Treat Acute Myeloid Leukemia Patients with Measurable Residual Disease before an Allogeneic Stem Cell Transplant
Purpose
Some people treated for acute myeloid leukemia (AML) with induction (initial) chemotherapy are left with minimal residual disease (MRD). With MRD, there is a small number of leukemia cells from the bone marrow remaining in the body. MRD increases the chance that the cancer will come back after a bone marrow transplant from a donor.
The drugs azacitidine and venetoclax may work well to get rid of or lower MRD in people with AML. Researchers are doing this study to see if this can be achieved with one treatment cycle of azacitidine and venetoclax. They hope that giving these drugs before a bone marrow transplant will reduce the chance of the leukemia coming back. Azacitidine is given intravenously (by vein) or as an injection, and venetoclax is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have AML with MRD after induction chemotherapy.
- Be planning to receive a bone marrow transplant from a donor.
- Be age 18 or older.
- You may join this study even if you need help taking care of yourself. You may also join even if you are in a bed or chair for more than half the time you’re awake.
Contact
For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.
Protocol
24-347Phase
Phase II (phase 2)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06773208ClinicalTrials.gov